Can Apellis Find a way to Inhibit the Complement System & Treat Intermediate AMD?

Can Apellis find a way to inhibit the complement system and treat intermediate AMD? - Eye on Innovation Podcast

[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 078″] Clinical trials of complement inhibitors recently have produced some disappointing results, but Apellis remains committed to demonstrating its own inhibitor can help bring relief to people battling geographic atrophy and AMD. 10 Top Topics in this OIS Podcast: What’s this about a Face Transplant? A successful spinout from Potentia. How…

Read More

Acucela

Participant: Ryo Kubota, MD, PhD Acucela is a clinical-stage biotechnology company that specializes in discovering and developing novel therapeutics to treat and slow the progression of sight-threatening ophthalmic diseases affecting millions of individuals worldwide. View Full Profile

Read More